Hikal Share Price Target 2025, 2026, 2027, 2028, 2030:- Hikal was established in 1988 as a trusted partner to pharmaceutical companies in the fields of pharmaceuticals, biotechnology, agrochemicals, and specialty chemicals. They provide world-class functional, intermediate, and research & development resources and solutions in a safe, secure, and confidential manner.
Therefore, in this article, we attempt to give a new perspective to Hikal stocks using technical and fundamental analysis.
Hikal Share Price Target 2025
Hikal’s superior infrastructure has been tested and approved by internationally recognized organizations such as the USFDA. Hikal is a company built on sustainable relationships. They are committed to providing value as a long-term partner. Through this commitment, they have earned the respect and recognition of some of the world’s leading companies.
The initial share price target for Hikal in 2025 will be around ₹440. For the second Hikal target, the stock price will be ₹500.
| Months | Hikal Share Price Target 2025 |
|---|---|
| January 2025 | Rs 440 |
| February 2025 | Rs 445 |
| March 2025 | Rs 450 |
| April 2025 | Rs 455 |
| May 2025 | Rs 465 |
| June 2025 | Rs 470 |
| July 2025 | Rs 475 |
| August 2025 | Rs 480 |
| September 2025 | Rs 485 |
| October 2025 | Rs 490 |
| November 2025 | Rs 495 |
| December 2025 | Rs 500 |
Hikal Share Price Target 2026
Hikal is engaged in research and development, as well as the production and sale of fine chemicals in the pharmaceutical and agrochemical industries. The company collaborates with innovative firms and provides solutions for contract research, optimization, and custom manufacturing. Its personnel have extensive experience managing various projects. Research and development is a central focus for Hikal, and they place a high priority on investing in world-class scientists and laboratory equipment.
Their R&D team is overseen by a scientific advisory board composed of distinguished scientists. They have an impressive track record in research and development. Their scientists have published numerous books and obtained patents. They have developed several new and cost-effective processes for many known APIs (Active Pharmaceutical Ingredients).
The initial share price target for Hikal in 2026 will be ₹510, while the second price target will be ₹600.
| Months | Hikal Share Price Target 2026 |
|---|---|
| January 2026 | Rs 510 |
| February 2026 | Rs 520 |
| March 2026 | Rs 525 |
| April 2026 | Rs 535 |
| May 2026 | Rs 540 |
| June 2026 | Rs 550 |
| July 2026 | Rs 560 |
| August 2026 | Rs 570 |
| September 2026 | Rs 575 |
| October 2026 | Rs 585 |
| November 2026 | Rs 590 |
| December 2026 | Rs 600 |
Hikal Share Price Target 2027
Hikal provides molecules for contract-based research and is a preferred partner for leading international companies at various stages of drug discovery and development. Supported by modern equipment and a team of experienced scientists, they focus on research involving new molecules. The company has a successful history of developing processes that do not break down and can be scaled up from the laboratory to kilogram scale and eventually to commercial scale. Its engineering expertise enables it to effectively set up chemical plants, control multiple processes, and develop solutions that comply with strict quality and safety guidelines.
The initial share price target for Hikal in 2027 will be ₹620, while the second target price will be ₹720.
| Months | Hikal Share Price Target 2027 |
|---|---|
| January 2027 | Rs 620 |
| February 2027 | Rs 630 |
| March 2027 | Rs 635 |
| April 2027 | Rs 645 |
| May 2027 | Rs 655 |
| June 2027 | Rs 660 |
| July 2027 | Rs 670 |
| August 2027 | Rs 680 |
| September 2027 | Rs 690 |
| October 2027 | Rs 700 |
| November 2027 | Rs 720 |
| December 2027 | Rs 720 |
Hikal Share Price Target 2028
Hikal has developed a method to ensure innovation. These processes include internal process analysis, identification, and quantification of contaminants. Custom manufacturing also optimizes the production of medium-sized essential materials for pharmaceutical and chemical companies worldwide. Its intermediate drugs are used in Phase 1, Phase 2, and Phase 3 clinical trials, as well as in new medicines used in commercial treatments.
The first share price target for Hikal in 2028 will be ₹730, and the second target price for the financial year 2025 will be approximately ₹870.
| Months | Hikal Share Price Target 2028 |
|---|---|
| January 2028 | Rs 730 |
| February 2028 | Rs 740 |
| March 2028 | Rs 760 |
| April 2028 | Rs 770 |
| May 2028 | Rs 780 |
| June 2028 | Rs 800 |
| July 2028 | Rs 810 |
| August 2028 | Rs 820 |
| September 2028 | Rs 840 |
| October 2028 | Rs 850 |
| November 2028 | Rs 860 |
| December 2028 | Rs 870 |
Hikal Share Price Target 2030
Hikal is a dedicated partner in the global pharmaceutical industry, supporting the pharmaceutical sector from the early stages of leadership to the introduction of new chemical ventures. Hikal’s expertise covers the entire spectrum, from traditional mixtures to complex chiral chemicals, and is backed by state-of-the-art analytical resources. They are the preferred choice for the world’s leading crop protection companies. International companies utilize their expertise in developing molecule-free processes and analytical methods.
The initial share price target for Hikal in 2030 will be ₹1,000, and the second target price will be ₹1,150 by the end of the decade.
| Months | Hikal Share Price Target 2030 |
|---|---|
| January 2030 | Rs 1000 |
| February 2030 | Rs 1010 |
| March 2030 | Rs 1030 |
| April 2030 | Rs 1040 |
| May 2030 | Rs 1060 |
| June 2030 | Rs 1070 |
| July 2030 | Rs 1080 |
| August 2030 | Rs 1100 |
| September 2030 | Rs 1110 |
| October 2030 | Rs 1120 |
| November 2030 | Rs 1130 |
| December 2030 | Rs 1150 |
Future Prospects of Hikal Share
Hikal has signed a multi-year contract with a world-renowned pharmaceutical company. This contract covers the development and provision of a specific API portfolio over a period of 10 years. Development will begin this year, and sales of the products will commence following successful development and crop sales.
Through this agreement, Hikal is entering the chemicals and products sector, thereby strengthening its vertical in animal health. To implement these APIs, Hikal and its customer will jointly invest in establishing various production facilities at their Panoli site in Gujarat.
Hikal Share Price Target F.A.Q.
– Where is Hikal’s headquarters located?
Hikal’s headquarters is located in Navi Mumbai, India.
– Who is the founder and executive chairman of Hikal?
Jai Hiremath is the founder and executive chairman of Hikal.
– What business is Hikal involved in?
Hikal is in the business of pharmaceutical services.
I hope that after reading the article on Hikal Share Price Target for 2025, 2026, 2027, 2028, and 2030, you have a good understanding of the kind of performance we might see in the company’s growth. If you still have any questions related to this article, don’t forget to mention them in the comments. Stay connected with Market in India for important information about such stocks in the stock market.
Also read:-